Dibigatran Market Report

Global and Region Dibigatran Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 02, 2022
  • PAGES：192
  • REPORT CODE：GMM989559
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Dibigatran market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Dibigatranmarket, defines the market attractiveness level of Dibigatran market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Dibigatran industry, describes the types of Dibigatran market, the applications of major players and the market size, and deeply analyzes the current situation of the global Dibigatran market and the development prospects and opportunities of Dibigatran industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Dibigatran market in Chapter 13.

    By Player:

    • GlaxoSmithKline Plc (UK)

    • Boehringer Ingelheim (Germany)

    • Bristol-Myers Squibb Company (US)

    • Abbott India Limited (India)

    • Eisai Inc (US)

    • Mitsubishi Tanabe Pharma Corporation (Japan)

    • Aspen Holdings (South Africa)

    • Pfizer Inc (US)

    • Teva Pharmaceutical Industries Ltd (Israel)

    • Sanofi SA (France)

    • Bayer Healthcare AG (Germany)

    By Type:

    • Pradaxa

    • Pradax

    • Prazaxa

    By End-User:

    • stroke

    • deep vein thrombosis

    • pulmonary embolism

    • systemic embolism

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Dibigatran Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Dibigatran Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Dibigatran Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Dibigatran Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Dibigatran Market Analysis and Outlook to 2022

    • 7.1 Global Dibigatran Consumption (2017-2022)

    • 7.2 United States Dibigatran Consumption (2017-2022)

    • 7.3 Europe Dibigatran Consumption (2017-2022)

    • 7.4 China Dibigatran Consumption (2017-2022)

    • 7.5 Japan Dibigatran Consumption (2017-2022)

    • 7.6 India Dibigatran Consumption (2017-2022)

    • 7.7 South Korea Dibigatran Consumption (2017-2022)

    8 Region and Country-wise Dibigatran Market Analysis and Outlook to 2028

    • 8.1 Global Dibigatran Consumption Forecast (2022-2028)

    • 8.2 United States Dibigatran Consumption Forecast (2022-2028)

    • 8.3 Europe Dibigatran Consumption Forecast (2022-2028)

    • 8.4 China Dibigatran Consumption Forecast (2022-2028)

    • 8.5 Japan Dibigatran Consumption Forecast (2022-2028)

    • 8.6 India Dibigatran Consumption Forecast (2022-2028)

    • 8.7 South Korea Dibigatran Consumption Forecast (2022-2028)

    9 Global Dibigatran Market Outlook by Types and Applications to 2022

    • 9.1 Global Dibigatran Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Pradaxa Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Pradax Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Prazaxa Consumption and Growth Rate (2017-2022)

    • 9.2 Global Dibigatran Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global stroke Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global deep vein thrombosis Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global pulmonary embolism Consumption and Growth Rate (2017-2022)

      • 9.2.4 Global systemic embolism Consumption and Growth Rate (2017-2022)

    10 Global Dibigatran Market Outlook by Types and Applications to 2028

    • 10.1 Global Dibigatran Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Pradaxa Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Pradax Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Prazaxa Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Dibigatran Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global stroke Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global deep vein thrombosis Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.3 Global pulmonary embolism Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.4 Global systemic embolism Consumption Forecast and Growth Rate (2022-2028)

    11 Global Dibigatran Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Dibigatran Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Dibigatran Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Dibigatran Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Dibigatran Market Competitive Analysis

    • 14.1 GlaxoSmithKline Plc (UK)

      • 14.1.1 GlaxoSmithKline Plc (UK) Company Details

      • 14.1.2 GlaxoSmithKline Plc (UK) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 GlaxoSmithKline Plc (UK) Dibigatran Product and Service

    • 14.2 Boehringer Ingelheim (Germany)

      • 14.2.1 Boehringer Ingelheim (Germany) Company Details

      • 14.2.2 Boehringer Ingelheim (Germany) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Boehringer Ingelheim (Germany) Dibigatran Product and Service

    • 14.3 Bristol-Myers Squibb Company (US)

      • 14.3.1 Bristol-Myers Squibb Company (US) Company Details

      • 14.3.2 Bristol-Myers Squibb Company (US) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Bristol-Myers Squibb Company (US) Dibigatran Product and Service

    • 14.4 Abbott India Limited (India)

      • 14.4.1 Abbott India Limited (India) Company Details

      • 14.4.2 Abbott India Limited (India) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Abbott India Limited (India) Dibigatran Product and Service

    • 14.5 Eisai Inc (US)

      • 14.5.1 Eisai Inc (US) Company Details

      • 14.5.2 Eisai Inc (US) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Eisai Inc (US) Dibigatran Product and Service

    • 14.6 Mitsubishi Tanabe Pharma Corporation (Japan)

      • 14.6.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Details

      • 14.6.2 Mitsubishi Tanabe Pharma Corporation (Japan) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Mitsubishi Tanabe Pharma Corporation (Japan) Dibigatran Product and Service

    • 14.7 Aspen Holdings (South Africa)

      • 14.7.1 Aspen Holdings (South Africa) Company Details

      • 14.7.2 Aspen Holdings (South Africa) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Aspen Holdings (South Africa) Dibigatran Product and Service

    • 14.8 Pfizer Inc (US)

      • 14.8.1 Pfizer Inc (US) Company Details

      • 14.8.2 Pfizer Inc (US) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Pfizer Inc (US) Dibigatran Product and Service

    • 14.9 Teva Pharmaceutical Industries Ltd (Israel)

      • 14.9.1 Teva Pharmaceutical Industries Ltd (Israel) Company Details

      • 14.9.2 Teva Pharmaceutical Industries Ltd (Israel) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Teva Pharmaceutical Industries Ltd (Israel) Dibigatran Product and Service

    • 14.10 Sanofi SA (France)

      • 14.10.1 Sanofi SA (France) Company Details

      • 14.10.2 Sanofi SA (France) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Sanofi SA (France) Dibigatran Product and Service

    • 14.11 Bayer Healthcare AG (Germany)

      • 14.11.1 Bayer Healthcare AG (Germany) Company Details

      • 14.11.2 Bayer Healthcare AG (Germany) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Bayer Healthcare AG (Germany) Dibigatran Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Dibigatran

    • Figure Dibigatran Picture

    • Table Global Dibigatran Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Dibigatran Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Dibigatran Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Dibigatran Consumption by Country (2017-2022)

    • Figure United States Dibigatran Consumption and Growth Rate (2017-2022)

    • Table Europe Dibigatran Consumption and Growth Rate (2017-2022)

    • Figure China Dibigatran Consumption and Growth Rate (2017-2022)

    • Figure Japan Dibigatran Consumption and Growth Rate (2017-2022)

    • Figure India Dibigatran Consumption and Growth Rate (2017-2022)

    • Figure South Korea Dibigatran Consumption and Growth Rate (2017-2022)

    • Figure Global Dibigatran Consumption Forecast by Country (2022-2028)

    • Figure United States Dibigatran Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Dibigatran Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Dibigatran Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Dibigatran Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Dibigatran Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Dibigatran Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pradaxa Consumption and Growth Rate (2017-2022)

    • Figure Global Pradax Consumption and Growth Rate (2017-2022)

    • Figure Global Prazaxa Consumption and Growth Rate (2017-2022)

    • Figure Global stroke Consumption and Growth Rate (2017-2022)

    • Figure Global deep vein thrombosis Consumption and Growth Rate (2017-2022)

    • Figure Global pulmonary embolism Consumption and Growth Rate (2017-2022)

    • Figure Global systemic embolism Consumption and Growth Rate (2017-2022)

    • Figure Global Pradaxa Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pradax Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prazaxa Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global stroke Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global deep vein thrombosis Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global pulmonary embolism Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global systemic embolism Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Dibigatran Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Dibigatran Export by Region (Top 5 Countries) (2017-2028)

    • Table GlaxoSmithKline Plc (UK) (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Plc (UK) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Plc (UK) Dibigatran Product and Service

    • Table Boehringer Ingelheim (Germany) (Foundation Year, Company Profile and etc.)

    • Table Boehringer Ingelheim (Germany) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Boehringer Ingelheim (Germany) Dibigatran Product and Service

    • Table Bristol-Myers Squibb Company (US) (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Company (US) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Company (US) Dibigatran Product and Service

    • Table Abbott India Limited (India) (Foundation Year, Company Profile and etc.)

    • Table Abbott India Limited (India) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbott India Limited (India) Dibigatran Product and Service

    • Table Eisai Inc (US) (Foundation Year, Company Profile and etc.)

    • Table Eisai Inc (US) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eisai Inc (US) Dibigatran Product and Service

    • Table Mitsubishi Tanabe Pharma Corporation (Japan) (Foundation Year, Company Profile and etc.)

    • Table Mitsubishi Tanabe Pharma Corporation (Japan) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mitsubishi Tanabe Pharma Corporation (Japan) Dibigatran Product and Service

    • Table Aspen Holdings (South Africa) (Foundation Year, Company Profile and etc.)

    • Table Aspen Holdings (South Africa) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Aspen Holdings (South Africa) Dibigatran Product and Service

    • Table Pfizer Inc (US) (Foundation Year, Company Profile and etc.)

    • Table Pfizer Inc (US) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc (US) Dibigatran Product and Service

    • Table Teva Pharmaceutical Industries Ltd (Israel) (Foundation Year, Company Profile and etc.)

    • Table Teva Pharmaceutical Industries Ltd (Israel) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Teva Pharmaceutical Industries Ltd (Israel) Dibigatran Product and Service

    • Table Sanofi SA (France) (Foundation Year, Company Profile and etc.)

    • Table Sanofi SA (France) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi SA (France) Dibigatran Product and Service

    • Table Bayer Healthcare AG (Germany) (Foundation Year, Company Profile and etc.)

    • Table Bayer Healthcare AG (Germany) Dibigatran Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer Healthcare AG (Germany) Dibigatran Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US